Background
Materials and methods
Animals and antibodies
Experimental autoimmune encephalomyelitis induction
In vivo administration of CCX771, a CXCR7 antagonist
Diffusion Tensor Imaging (DTI) and analysis
Histological and immunofluorescent analyses
Statistical analysis
Results
CXCR7 antagonism promotes complete clinical recovery during EAE
saline | vehicle | 5 mg | vehicle to 10 mg | 10 mg | |
---|---|---|---|---|---|
saline
|
--
| ns | * | ns | ** |
vehicle
| ns |
--
| * | ns | ** |
5 mg
| * | * |
--
| ns | ns |
vehicle to 10 mg
| ns | ns | ns |
--
| ns |
10 mg
| ** | ** | ns | ns |
--
|
saline | vehicle | 5 mg | vehicle to 10 mg | 10 mg | |
---|---|---|---|---|---|
saline
|
--
| ns | ns | *** | *** |
vehicle
| ns |
--
| ns | *** | *** |
5 mg
| ns | ns |
--
| * | * |
vehicle to 10 mg
| *** | *** | * |
--
| ns |
10 mg
| *** | *** | * | ns |
--
|
DTI reveals treatment efficacy of CXCR7 antagonist on EAE mice
CXCR7 antagonism does not alter myelin levels during recovery from EAE
CXCR7 antagonism ameliorates persistent CNS inflammation
10 mg | vehicle to 10 mg | 5 mg | vehicle | saline | |
---|---|---|---|---|---|
10 mg
|
--
| ns | ns | *** | ** |
vehicle to 10 mg
| ns |
--
| ns | ** | ns |
5 mg
| ns | ns |
--
| *** | ns |
vehicle
| *** | ** | *** |
--
| ns |
saline
| ** | ns | ns | ns |
--
|